Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...